Roche (RHHBY) said the recent death of a Duchenne muscular dystrophy patient in Brazil who had been treated with Sarepta’s (SRPT) gene therapy Elevidys is unrelated to the treatment, Naomi Kresge of Bloomberg reports. The boy wasn’t a clinical trial participant and the reporting physician assessed his death as being unrelated to Elevidys, Roche said, according to Bloomberg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT: